← Back to patent-cliff list
Levornidazole Capsules(Hunan Zhengtai Jinhu Pharma)
Tier C — Watch / tradeLevornidazole Capsules(Hunan Zhengtai Jinhu Pharma)
-
Originator
2022
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：DNA
Indications (approved)：阿米巴感染, 贾第虫感染, 毛滴虫病, 厌氧菌感染
Regional status
US
-
EU
-
China
Approved
2022-01-30
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Levornidazole Capsules(Hunan Zhengtai Jinhu Pharma)?
Approved indications include: 阿米巴感染, 贾第虫感染, 毛滴虫病, 厌氧菌感染.
When does the Levornidazole Capsules(Hunan Zhengtai Jinhu Pharma) patent expire?
No public expiry year is available for Levornidazole Capsules(Hunan Zhengtai Jinhu Pharma) yet; this page updates once verified.
How do I get a quote for Levornidazole Capsules(Hunan Zhengtai Jinhu Pharma) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-27